Nicolas Clementy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5943983/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A leadless pacemaker in the real-world setting: The Micra Transcatheter Pacing System Post-Approval Registry. Heart Rhythm, 2017, 14, 1375-1379.	0.7	251
2	Updated performance of the Micra transcatheter pacemaker in the real-world setting: A comparison to the investigational study and a transvenous historical control. Heart Rhythm, 2018, 15, 1800-1807.	0.7	239
3	Effects of remote monitoring on clinical outcomes and use of healthcare resources in heart failure patients with biventricular defibrillators: results of the MOREâ€CARE multicentre randomized controlled trial. European Journal of Heart Failure, 2017, 19, 416-425.	7.1	165
4	Stroke and Major Bleeding Risk in Elderly Patients Aged ≥75 Years With Atrial Fibrillation. Stroke, 2015, 46, 143-150.	2.0	116
5	Accelerometer-based atrioventricular synchronous pacing with a ventricular leadless pacemaker: Results from the Micra atrioventricular feasibility studies. Heart Rhythm, 2018, 15, 1363-1371.	0.7	116
6	Patients With Ischemic Stroke and Incident Atrial Fibrillation. Stroke, 2015, 46, 2432-2437.	2.0	77
7	Incidence and predictors of sudden death, major conduction defects and sustained ventricular tachyarrhythmias in 1388 patients with myotonic dystrophy type 1. European Heart Journal, 2017, 38, ehw569.	2.2	59
8	Should Atrial Fibrillation Patients With Only 1 Nongender-Related CHA ₂ DS ₂ -VASc Risk Factor Be Anticoagulated?. Stroke, 2016, 47, 1831-1836.	2.0	59
9	Leadless Pacemaker Implantation inÂHemodialysis Patients. JACC: Clinical Electrophysiology, 2019, 5, 162-170.	3.2	54
10	Prognostic value of CHA ₂ DS ₂ -VASc score in patients with â€~non-valvular atrial fibrillation' and valvular heart disease: the Loire Valley Atrial Fibrillation Project. European Heart Journal, 2015, 36, 1822.2-1830.	2.2	53
11	Galectin-3 in Atrial Fibrillation: Mechanisms and Therapeutic Implications. International Journal of Molecular Sciences, 2018, 19, 976.	4.1	52
12	Serum Galectin-3 Levels Predict Recurrences after Ablation of Atrial Fibrillation. Scientific Reports, 2016, 6, 34357.	3.3	45
13	Long-term follow-up on high-rate cut-off programming for implantable cardioverter defibrillators in primary prevention patients with left ventricular systolic dysfunction. Europace, 2012, 14, 968-974.	1.7	41
14	Tachycardiomyopathy Secondary to Nonreentrant Atrioventricular Nodal Tachycardia: Recovery After Slow Pathway Ablation. PACE - Pacing and Clinical Electrophysiology, 2007, 30, 925-928.	1.2	34
15	Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis. Thrombosis and Haemostasis, 2016, 115, 1056-1063.	3.4	33
16	Development and Validation of a New Scoring System to Predict Survival in Patients With Myotonic Dystrophy Type 1. JAMA Neurology, 2018, 75, 573.	9.0	32
17	Changes in glomerular filtration rate and outcomes in patients with atrial fibrillation. American Heart Journal, 2018, 198, 39-45.	2.7	31
18	Pacemaker Implantation After Balloon―or Selfâ€Expandable Transcatheter Aortic Valve Replacement in Patients With Aortic Stenosis, Journal of the American Heart Association, 2020, 9. e015896.	3.7	30

NICOLAS CLEMENTY

#	Article	IF	CITATIONS
19	Risk stratification of cardiovascular and heart failure hospitalizations using integrated device diagnostics in patients with a cardiac resynchronization therapy defibrillator. Europace, 2018, 20, e69-e77.	1.7	29
20	Very high rate programming in primary prevention patients with reduced ejection fraction implanted with a defibrillator: Results from a large multicenter controlled study. Heart Rhythm, 2017, 14, 211-217.	0.7	24
21	Incident Comorbidities, Aging and the Risk of Stroke in 608,108 Patients with Atrial Fibrillation: A Nationwide Analysis. Journal of Clinical Medicine, 2020, 9, 1234.	2.4	24
22	Pacemaker complications and costs: a nationwide economic study. Journal of Medical Economics, 2019, 22, 1171-1178.	2.1	22
23	Mortality After Atrioventricular Nodal Radiofrequency Catheter Ablation With Permanent Ventricular Pacing in Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2016, 9, .	4.8	21
24	Galectin-3 level predicts response to ablation and outcomes in patients with persistent atrial fibrillation and systolic heart failure. PLoS ONE, 2018, 13, e0201517.	2.5	20
25	Position paper for management of elderly patients with pacemakers and implantable cardiac defibrillators: Groupe de Rythmologie et Stimulation Cardiaque de la Société Française de Cardiologie and Société Française de Gériatrie et Gérontologie. Archives of Cardiovascular Diseases, 2016, 109, 563-585.	1.6	19
26	Stroke and Thromboembolism in Patients With Atrial Fibrillation and Mitral Regurgitation. Circulation: Arrhythmia and Electrophysiology, 2019, 12, e006990.	4.8	17
27	Stroke, thromboembolism and bleeding in patients with atrial fibrillation according to the EHRA valvular heart disease classification. International Journal of Cardiology, 2018, 260, 93-98.	1.7	15
28	Galectin-3 in patients undergoing ablation of atrial fibrillation. IJC Metabolic & Endocrine, 2014, 5, 56-60.	0.5	11
29	Galectin-3 predicts response and outcomes after cardiac resynchronization therapy. Journal of Translational Medicine, 2018, 16, 299.	4.4	11
30	Outcomes associated with pacemaker implantation following transcatheter aortic valve replacement: A nationwide cohort study. Heart Rhythm, 2021, 18, 2027-2032.	0.7	9
31	Insufficiency of electrocardiogram alone in predicting infrahisian abnormalities in patients with type 1 myotonic dystrophy. International Journal of Cardiology, 2014, 172, 625-627.	1.7	8
32	The Defibrillation Conundrum: New Insights into the Mechanisms of Shock-Related Myocardial Injury Sustained from a Life-Saving Therapy. International Journal of Molecular Sciences, 2021, 22, 5003.	4.1	8
33	Benefits of an early management of palpitations. Medicine (United States), 2018, 97, e11466.	1.0	7
34	Nonsustained Ventricular Tachycardia at the Time ofÂImplantation Predicts Appropriate Therapies on Rapid Ventricular Arrhythmia in Primary Prevention Patients With Nonischemic Cardiomyopathy. JACC: Clinical Electrophysiology, 2017, 3, 1338-1339.	3.2	6
35	Outcomes in patients with acute myocardial infarction and history of illicit drug use: a French nationwide analysis. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 1027-1037.	1.0	6
36	Successful 'quadrangular' pacing in a non-responder patient to cardiac resynchronization therapy. European Heart Journal, 2011, 32, 2215-2215.	2.2	5

NICOLAS CLEMENTY

1.7

0

#	Article	IF	CITATIONS
37	Acute pathophysiological myocardial changes following intra-cardiac electrical shocks using a proteomic approach in a sheep model. Scientific Reports, 2020, 10, 20252.	3.3	5
38	Cardiovascular outcomes after cardiac resynchronization therapy in cardiac amyloidosis. ESC Heart Failure, 2022, 9, 740-750.	3.1	5
39	Major ST-segment elevation hiding acute severe pancreatitis. American Journal of Emergency Medicine, 2010, 28, 116.e1-116.e3.	1.6	4
40	Programming implantable cardioverter-defibrillators in primary prevention: Higher or later. Archives of Cardiovascular Diseases, 2014, 107, 308-318.	1.6	4
41	Severe recurrent vasovagal syncope and multidisciplinary rehabilitation: A prospective randomized pilot study. International Journal of Cardiology, 2015, 187, 658-659.	1.7	4
42	Leadless cardiac pacemaker implantation in patient with active tricuspid endocarditis. Europace, 2021, 23, 1794-1794.	1.7	4
43	Electrogram morphology discriminators in implantable cardioverter defibrillators: A comparative evaluation. Journal of Cardiovascular Electrophysiology, 2020, 31, 1493-1506.	1.7	3
44	Leadless pacemaker implant with concomitant atrioventricular node ablation: Experience with the Micra transcatheter pacemaker. Journal of Cardiovascular Electrophysiology, 2021, 32, 832-841.	1.7	3
45	Leadless pacemakers in critically ill patients requiring prolonged cardiac pacing: A multicenter international study. Journal of Cardiovascular Electrophysiology, 2021, 32, 2522-2527.	1.7	3
46	Leadless pacemakers: learning from experience. Europace, 2019, 21, 356-356.	1.7	2
47	Three-dimensional interlead distance predicts response and outcomes after cardiac resynchronization therapy. Archives of Cardiovascular Diseases, 2017, 110, 590-598.	1.6	1
48	Prognosis of Type 2 Myocardial Infarction Patients Implanted With a Prophylactic Defibrillator (from) Tj ETQq0 0	0 rgBT /Ov 1.6	verlock 10 Ti
49	To the Editor—Fear does not avoid the danger!. Heart Rhythm, 2021, 18, 161.	0.7	1
50	Atrioventricular Nodal Reentrant Tachycardia Ablation Using Mini-Electrode Recordings. Journal of Clinical Medicine, 2022, 11, 282.	2.4	1
51	Physiological pacing with a DFâ€l single chamber defibrillator in a patient with permanent atrial fibrillation and heart block: A case report. Journal of Cardiovascular Electrophysiology, 2022, , .	1.7	1
52	Atrial flutter: Right, left, or both?. Heart Rhythm, 2012, 9, 844-845.	0.7	0
53	Pacemaker "Dysfunction―Treated by Radiofrequency Ablation. PACE - Pacing and Clinical Electrophysiology, 2013, 36, 772-774.	1.2	0

⁵⁴ How to upgrade a leadless pacemaker to cardiac resynchronization therapy. Journal of Cardiovascular Electrophysiology, 2019, 30, 2578-2581.

NICOLAS CLEMENTY

#	Article	IF	CITATIONS
55	End-of-service management of leadless cardiac pacemakers: a case report. Europace, 2019, 21, 1245-1245.	1.7	0
56	Distalâ€ŧoâ€proximal delay for ablation of premature ventricular contractions. Journal of Cardiovascular Electrophysiology, 2019, 30, 205-211.	1.7	0
57	The ICâ€D score for predicting prophylactic cardioverterâ€defibrillator implantation following acute myocardial infarction. PACE - Pacing and Clinical Electrophysiology, 2021, 44, 973-979.	1.2	0